Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Podcast: key readouts from ESC and ERS

The healthcare team dive into the latest data and emerging trends from the ESC Congress and ERS Congress.

Latest news

Why China’s rise needs to be taken with a pinch of salt

Though recent dealmaking illustrates China’s rapid rise in global biopharma, experts suggest this could be about to plateau.

HHS appoints permanent FDA CBER, CDER heads 

The HHS sets out these permanent senior leadership positions as it looks to “reform” the FDA.

Solstice Oncology secures $225m to drive porustobart’s development for cancer

The funding round was led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors.

Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion

Thoracic oncologists previously touted Hyrnuo’s potential in HER2-mutant NSCLC in both the first- and second-line settings.

Pharma’s R&D, commercial approach shifts amid global policy evolution

A survey of 175 pharma executives highlights an increasing reluctance to launch in lower-value markets, alongside a heightened focus on RWE.

TwoStep Therapeutics raises $62.5m in funding to advance TS-104

TwoStep will begin a Phase I study of TS-104, with patient enrolment expected to commence later this year.

ERS 2026: GB-0895 clinical results show potential of next-gen anti-TSLP for asthma

As a lymphocyte-stimulating cytokine, TSLP has been shown to drive the inflammatory response in the airways of patients with severe asthma.